Ownership and insider activity for Ocugen, Inc. (OCGN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigme...
Price
| Price | $1.00 |
| Market Cap | $339M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $31.9M | $7.1M | $15.5M | $7.4M | $24.0M | $95.0M | $77.6M | $39.5M | $58.5M | $18.6M |
| Short-term Investments | 0 | $900000 | 0 | 0 | 0 | 0 | $13.4M | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $32.1M | $8.2M | $16.4M | $15.8M | $25.9M | $102.6M | $98.5M | $43.0M | $61.7M | $24.3M |
| Property, Plant & Equipment | $3.9M | $2.7M | $141000 | $222464 | $633000 | $1.2M | $6.1M | $17.3M | $16.6M | $14.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $36.1M | $11.0M | $17.4M | $16.8M | $27.4M | $105.8M | $108.6M | $64.5M | $82.4M | $43.5M |
| Accounts Payable | $1.9M | $776000 | $1.6M | $1.9M | $395000 | $2.3M | $8.1M | $3.2M | $4.2M | $6.2M |
| Short-term Debt | $583000 | $178000 | 0 | 0 | $234000 | 0 | 0 | 0 | $1.3M | $1.2M |
| Total Current Liabilities | $5.2M | $3.8M | $2.9M | $4.5M | $3.6M | $7.0M | $28.5M | $17.1M | $21.6M | $23.0M |
| Long-term Debt | $178000 | 0 | $1.0M | $1.1M | $1.8M | $1.7M | $2.3M | $2.8M | $27.3M | $27.5M |
| Total Liabilities | $22.5M | $22.3M | $17.9M | $5.8M | $5.8M | $9.9M | $34.7M | $24.0M | $52.8M | $55.7M |
| Retained Earnings | -$181.8M | -$208.2M | -$216.8M | -$51.5M | -$73.3M | -$131.7M | -$223.1M | -$286.2M | -$340.2M | -$408.1M |
| Total Equity | $13.6M | -$11.3M | -$458000 | $11.0M | $21.6M | $95.8M | $74.0M | $40.6M | $29.6M | -$12.2M |
| Total Debt | $761000 | $178000 | $238000 | $1.4M | $2.5M | $3.3M | $6.4M | $6.9M | $32.5M | $33.1M |
| Net Debt | -$31.1M | -$7.8M | -$15.3M | -$6.0M | -$21.5M | -$91.7M | -$84.6M | -$32.5M | -$26.0M | $14.6M |
| Working Capital | $26.9M | $4.4M | $13.5M | $11.2M | $22.3M | $95.6M | $70.0M | $25.9M | $40.1M | $1.3M |
Financial Health
| Debt / Equity | -5.31 |
| Current Ratio | 0.80 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -13.40 |
Profitability
| Return on Equity | 1688.22% |
| Return on Invested Capital | -92.68% |
| Return on Assets | -65.87% |
| Gross Margin | 100.00% |
| Operating Margin | -1504.43% |
| Net Margin | -1786.27% |
Related companies: ADCT · ALMS · CMPX · FULC · LCTX · LXRX · NGNE
Explore sector: Healthcare · Biotechnology
More sections of OCGN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks